Leerink Swann Starts DexCom (DXCM) at Market Perform; Positive Long-Term, But Some Near-Term Hurdles
Tweet
Share
E-mailGet Alerts DXCM Hot Sheet
Price: $89.75 -1.89%
Rating Summary:
32 Buy, 7 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
32 Buy, 7 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Leerink Swann initiates coverage on DexCom (NASDAQ: DXCM) with a Market Perform. PT $12.00.
Leerink analyst said, "Longer-term, we view the continuous glucose monitoring (CGM) market as compelling, potentially $1B+ as it targets a large and undertreated patient population in Type 1 diabetics. DXCM seems well-positioned as FDA and industry work towards an “artificial pancreas"."
However, Leerink's analysts points out to four near-term issues.: 1) low awareness; 2) a "nice-to-have" mindset for CGM vs. a “must-have” in a cost-conscious environment; and 3) limited margin expansion with higher clinical trial spend and the Gen 4 manufacturing transition post 1Q13 launch."
For an analyst ratings summary and ratings history on DexCom click here. For more ratings news on DexCom click here.
Shares of DexCom closed at $10.43 yesterday.
Leerink analyst said, "Longer-term, we view the continuous glucose monitoring (CGM) market as compelling, potentially $1B+ as it targets a large and undertreated patient population in Type 1 diabetics. DXCM seems well-positioned as FDA and industry work towards an “artificial pancreas"."
However, Leerink's analysts points out to four near-term issues.: 1) low awareness; 2) a "nice-to-have" mindset for CGM vs. a “must-have” in a cost-conscious environment; and 3) limited margin expansion with higher clinical trial spend and the Gen 4 manufacturing transition post 1Q13 launch."
For an analyst ratings summary and ratings history on DexCom click here. For more ratings news on DexCom click here.
Shares of DexCom closed at $10.43 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- Lake Street Starts RF Industries Ltd. (RFIL) at Buy
- RBC Capital Starts Krystal Biotech (KRYS) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
